For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Amortization of intangible asset | - | 0 | 0 | 0 |
| Total revenues | 53,544 | 57,622 | 58,766 | 62,472 |
| Cost of product and other revenue | 12,290 | 12,535 | 9,383 | 9,919 |
| Restructuring | - | 0 | 0 | 0 |
| Total cost of goods sold | 12,290 | 12,535 | 9,383 | 9,919 |
| Research and development | 14,807 | 26,648 | 14,944 | 11,013 |
| Selling, general and administrative | 30,436 | 26,089 | 29,094 | 26,555 |
| License | 707 | 903 | 896 | 896 |
| Total operating expenses | 45,950 | 53,640 | 44,934 | 38,464 |
| Income (gain) from operations | -4,696 | -8,553 | 4,449 | 14,089 |
| Interest expense | -4,691 | -4,827 | -4,748 | -6,834 |
| Loss on extinguishment of debt | - | 0* | 0 | 0 |
| Other income | 3 | -117 | -10 | -28 |
| Loss on termination of lease | - | 0* | - | - |
| Change in fair value of warrant liability | -456 | -2,262 | -1,464 | 6,980 |
| Income (loss) before income taxes | -8,928 | -11,235 | 1,155 | 247 |
| Income tax expense | 126 | 1,009 | 615 | - |
| Net income (loss) | -9,054 | -12,244 | 540 | 247 |
| Comprehensive income (loss) | -9,054 | -12,244 | 540 | 247 |
| Basic EPS | -0.03 | -0.046 | 0 | 0 |
| Diluted EPS | -0.03 | -0.051 | 0 | 0 |
| Basic Average Shares | 267,046,755 | 265,781,476 | 264,786,432 | 262,565,500 |
| Diluted Average Shares | 267,046,755 | 241,551,533 | 274,372,722 | 271,104,020 |
Akebia Therapeutics, Inc. (AKBA)
Akebia Therapeutics, Inc. (AKBA)